Metabolic Codependencies in the Tumor Microenvironment
- PMID: 33504580
- PMCID: PMC8102306
- DOI: 10.1158/2159-8290.CD-20-1211
Metabolic Codependencies in the Tumor Microenvironment
Abstract
Metabolic reprogramming enables cancer cell growth, proliferation, and survival. This reprogramming is driven by the combined actions of oncogenic alterations in cancer cells and host cell factors acting on cancer cells in the tumor microenvironment. Cancer cell-intrinsic mechanisms activate signal transduction components that either directly enhance metabolic enzyme activity or upregulate transcription factors that in turn increase expression of metabolic regulators. Extrinsic signaling mechanisms involve host-derived factors that further promote and amplify metabolic reprogramming in cancer cells. This review describes intrinsic and extrinsic mechanisms driving cancer metabolism in the tumor microenvironment and how such mechanisms may be targeted therapeutically. SIGNIFICANCE: Cancer cell metabolic reprogramming is a consequence of the converging signals originating from both intrinsic and extrinsic factors. Intrinsic signaling maintains the baseline metabolic state, whereas extrinsic signals fine-tune the metabolic processes based on the availability of metabolites and the requirements of the cells. Therefore, successful targeting of metabolic pathways will require a nuanced approach based on the cancer's genotype, tumor microenvironment composition, and tissue location.
©2021 American Association for Cancer Research.
Conflict of interest statement
CONFLICT OF INTEREST DISCLOSURE
P.D. has nothing to disclose. A.C.K. has financial interests in Vescor Therapeutics, LLC. A.C.K. is an inventor with patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer, targeting GOT1 as a therapeutic approach, and the autophagic control of iron metabolism. A.C.K. is on the SAB of Rafael/Cornerstone Pharmaceuticals. A.C.K. is a consultant for Deciphera Pharmaceuticals. R.A.D. is a co-founder, advisor, and/or director of Tvardi Therapeutics, Asylia Therapeutics, Stellanova Therapeutics, Nirogy Therapeutics and Sporos Bioventures. Tvardi and Nirogy are developing STAT3 and MCT inhibitors, respectively.
Figures


Similar articles
-
Depressive Disorder Affects TME and Hormonal Changes Promoting Tumour Deterioration Development.Immunology. 2025 Aug;175(4):403-418. doi: 10.1111/imm.13933. Epub 2025 May 8. Immunology. 2025. PMID: 40341563 Review.
-
The "life code": A theory that unifies the human life cycle and the origin of human tumors.Semin Cancer Biol. 2020 Feb;60:380-397. doi: 10.1016/j.semcancer.2019.09.005. Epub 2019 Sep 12. Semin Cancer Biol. 2020. PMID: 31521747 Review.
-
Targeting glutamine metabolism as a potential target for cancer treatment.J Exp Clin Cancer Res. 2025 Jul 1;44(1):180. doi: 10.1186/s13046-025-03430-7. J Exp Clin Cancer Res. 2025. PMID: 40598593 Free PMC article. Review.
-
Unraveling the role of GPCR signaling in metabolic reprogramming and immune microenvironment of lung adenocarcinoma: a multi-omics study with experimental validation.Front Immunol. 2025 Jun 6;16:1606125. doi: 10.3389/fimmu.2025.1606125. eCollection 2025. Front Immunol. 2025. PMID: 40547013 Free PMC article.
-
An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.Future Oncol. 2025 Mar;21(6):715-735. doi: 10.1080/14796694.2025.2461443. Epub 2025 Feb 12. Future Oncol. 2025. PMID: 39936282 Review.
Cited by
-
The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors.Molecules. 2023 Dec 22;29(1):75. doi: 10.3390/molecules29010075. Molecules. 2023. PMID: 38202657 Free PMC article. Review.
-
Unfolding the mysteries of heterogeneity from a high-resolution perspective: integration analysis of single-cell multi-omics and spatial omics revealed functionally heterogeneous cancer cells in ccRCC.Aging (Albany NY). 2024 Jun 26;16(13):10943-10971. doi: 10.18632/aging.205974. Epub 2024 Jun 26. Aging (Albany NY). 2024. PMID: 38944814 Free PMC article.
-
T proliferating cells derived autophagy signature associated with prognosis and immunotherapy resistance in a pan-cancer analysis.iScience. 2023 Dec 8;27(1):108701. doi: 10.1016/j.isci.2023.108701. eCollection 2024 Jan 19. iScience. 2023. PMID: 38222108 Free PMC article.
-
Genetic and biological hallmarks of colorectal cancer.Genes Dev. 2021 Jun;35(11-12):787-820. doi: 10.1101/gad.348226.120. Genes Dev. 2021. PMID: 34074695 Free PMC article. Review.
-
CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma.Front Immunol. 2022 Feb 22;13:806877. doi: 10.3389/fimmu.2022.806877. eCollection 2022. Front Immunol. 2022. PMID: 35273597 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical